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SUMMARY 
The role of somatic genetic variants in the pathogenesis of intracranial aneurysm formation is 
unknown. We identified a 23-year-old man with progressive right sided intracranial aneurysms, 
ipsilateral to an impressive cutaneous phenotype. The index individual underwent a series of 
genetic evaluations for known connective tissue disorders that were unrevealing. Paired sample 
exome sequencing between blood and fibroblasts derived from the diseased areas detected a single 
novel variant within the platelet-derived growth factor receptor  gene (PDGFRB) 
juxtamembrane-coding region predicted to cause a p.(Tyr562Cys) [g.149505130T>C 
(GRCh37/hg19); c.1685A>G] change. Variant allele fractions ranged from 18·75% to 53·33% 
within histologically abnormal tissue, suggesting post-zygotic or somatic mosaicism. In an 
independent cohort of aneurysm specimens, we detected somatic activating PDGFRB variants in 
the juxtamembrane domain or kinase activation loop in 4/6 fusiform aneurysms (and 0/38 saccular 
aneurysms, Fisher’s Exact Test p<0·001). PDGFRB-variant, but not wild type, patient cells were 
found to have overactive auto-phosphorylation with downstream activation of ERK, SRC and 
AKT. Expression of discovered variants demonstrated non-ligand dependent auto-
phosphorylation, responsive to the kinase inhibitor sunitinib. Somatic gain-of-function variants in 
PDGFRB are a novel mechanism in the pathophysiology of fusiform cerebral aneurysms and 
suggest a potential role for targeted therapy with kinase inhibitors. 
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Intracranial aneurysms occur in approximately 2% of the population with a rupture risk of 
6 per 100,000 individual-years 1,2. There are two types of aneurysms, the more common saccular 
(90-95%) and fusiform (4-8%)1,2. Saccular aneurysms are abnormal arterial outpouchings at 
branch points with histological loss of the media and intima. Fusiform aneurysms are 
circumferential abnormal arterial dilatation with histological medial and intimal hyperplasia. The 
size, location in the cerebrovascular tree and type of aneurysm all influence the natural history of 
this disease1,2. Abundant evidence supports a genetic component to the etiology of intracranial 
aneurysms1-7. The pathogenesis of cerebral aneurysm formation and rupture is complex and 
involves both environmental2 and genetic factors defined by twin, linkage and genome wide 
association studies3,4,5. Several genetic syndromes are associated with intracranial aneurysms, 
conferring increased risk compared to the general population1-3. Studies in mono and dizygotic 
twins also suggest both genetic and environmental contributions5. Established environmental risk 
factors, which may somatically alter coding regions of the genome, include cigarette smoking and 
hypertension1,2. The role of post-zygotic variants of genes that function in critical intracellular 
signaling pathways has been established for several types of overgrowth syndromes8,9 and vascular 
malformations10-16, but the role of somatic genetic alterations or mosaicism in intracranial 
aneurysms remains unknown. 
The index individual was first treated for a dissecting fusiform paraclinoid internal carotid 
artery aneurysm at 9 years of age. All individuals’ data and specimen collection were reviewed 
and approved by the University of Washington Institutional Review Board and Human Subjects 
Division. The individual was noted to have an impressive ipsilateral cutaneous phenotype. 
Fourteen years later, he developed a giant dissecting fusiform aneurysm of the right vertebral 
artery, which was previously normal by angiography (Fig. 1A-C and Fig. S1 in the Supplementary 
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Appendix). He had apparently normal cognition with no neurological deficits or other birth defects. 
No other abnormalities were found on brain (including intracranial calcifications), cardiovascular, 
or peripheral vascular imaging. He later developed both radial and coronary artery aneurysms (Fig. 
S1 J,K in the Supplementary Appendix), but never aortic aneurysm or dissection, underlying his 
dermal phenotype. Family history was negative. The left neurovascular tree remained normal (Fig. 
S1 C,E in the Supplementary Appendix). Detailed phenotype information for this individual is 
shown in Supplementary Appendix Fig. S1. He underwent a series of operations for treatment of 
the giant, rapidly growing fusiform vertebral aneurysm. DNA was extracted from multiple 
vascular and perivascular tissue samples (Fig. 1K) obtained during surgery. Initial variant 
discovery was carried out using paired sample exome sequencing to an average depth of ~150x 
between blood and fibroblasts derived from the diseased areas (>99% of the exome was covered 
for all samples). Exome sequencing was performed on blood and abnormal tissue using a 
customized exome capture probe set from the UW Medicine Center for Precision Diagnostics that 
is built upon the xGen Exome Research Panel v1.0 (IDT) backbone. Initial variant discovery was 
carried out using a comparison between blood and diseased area cultured fibroblast exomes 
sequenced to an average depth of ~150x on the Illumina HiSeq 2500 platform. Subsequent exome 
sequencing was performed on other diseased specimens and healthy radial artery (Fig. 1K and L) 
to at least 40x average depth (>99% of exome). Resulting reads were aligned using BWA-MEM 
(v0.7.5) following the Broad Institute’s GATK best practices. Somatic variants were identified 
using MuTect (v1.1.7) with default parameters. Our analysis detected a single novel variant within 
the platelet-derived growth factor receptor  gene (PDGFRB) juxtamembrane-coding region 
(p.Tyr562Cys [g.149505130T>C (GRCh37/hg19); c.1685A>G]). Variant allele fractions ranged 
from 18·75% to 53·33% within histologically abnormal tissue (Fig. 1D-L). No other somatic 
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variants were found. The highest allele fractions were found in a specimen from an occipital artery 
aneurysm (Fig. 1D-I and Fig. S2 in the Supplementary Appendix). This PDGFRB variant was not 
found in DNA isolated from blood or histologically normal, left-sided, radial artery (Fig. 1J-L), 
confirming post-zygotic or somatic mosaicism. 
PDGFRB encodes a conserved transmembrane receptor tyrosine kinase involved in diverse 
signaling processes during embryonal development17-21. PDGFRB is normally expressed in several 
cell types, including pericytes and vascular smooth muscle cells, and has an essential role in 
vascular progenitor cell signaling19-21.  Based on the findings in the individual described above, we 
performed targeted sequencing of PDGFRB in a validation cohort of 50 aneurysm and arterial 
walls (Fig. S3 in the Supplementary Appendix). The validation cohort was sequenced similarly to 
the exome sequencing performed on the index individual with the exception that a custom capture 
probe set (IDT) was used rather than the full exome. Variants were batch-identified across the 
cohort using the Platypus variant caller (v0.8.1), using a minimum variant allele fraction of 2%, a 
minimum coverage of 5 reads, and a minimum posterior probability of 0 (no variant reads) 
allowing more inclusive initial analysis. Germline variants and sequencing artifacts were further 
filtered out with an in-house script. All somatic variants were analyzed with IGV (v2.3.71) and 
functionally annotated with Oncotator (v1.9.3.0). Targeted sequencing revealed four variants in 
three additional sporadic individual cases: a variant within the juxtamembrane domain predicted 
to result in a four amino acid in-frame deletion (p.Tyr562_Arg565del) in exon 12, and two 
additional variants in the activation loop of the kinase domain (p.Asp850Tyr and 
p.Arg849_Lys860delinsHisAlaGlyLeuGluLeuHisLeuGln) in exon 18 (Fig. 2A). The latter variant 
was comprised of two deletions located in cis that together are predicted to result in a complex in-
frame insertion-deletion (Fig. S6 in the Supplementary Appendix). Variants were only found in 
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fusiform aneurysms (3/5, 60%), radiographically and histologically similar to our index individual 
(Fig. 2B-F and Fig. S4 in the Supplementary Appendix). All saccular aneurysms had wild-type 
PDGFRB.  
Exome sequencing was performed on aneurysm walls and control tissues from all three 
PDGFRB-variant sporadic fusiform aneurysms (see the Supplementary Appendix). All aneurysm 
samples were sequenced to at least 175x (>99% of exome) and control samples to at least 90x 
(>99% of exome) average coverage with the exception of lymph node DNA from the VAL-44 
individual. Additional sequencing was added to the PDGFRB variant region of the lymph node 
DNA (non-aneurysm control DNA) with the custom capture probe set in order to study a germline 
contribution for VAL-44. The aneurysm exome of VAL-44 was analyzed on its own. For every 
available control tissue, complete pairs were analyzed with a variant using FreeBayes (v1.0.2), 
Strelka2 (v2.0.17), VarDict (v1.5.1), and VarScan2 (v2.4.3), and the output was filtered with an 
in-house script and confirmed with manual inspection on IGV. For the VAL-44 aneurysm without 
a good-quality control, variant calling was done with FreeBayes, Platypus, and Vardict and the 
output was filtered with an in-house script and confirmed with manual inspection on IGV. Exome 
sequencing of aneurysm and normal tissue DNA revealed only recurrent PDGFRB variants (Fig. 
S6 and S7 in the Supplementary Appendix), suggesting a causal role in the formation of sporadic 
fusiform aneurysms. DNA was available from blood and/or unaffected healthy tissue, to explore 
the germline contribution of the variant in all cases (Fig. S7 in the Supplementary Appendix). 
The skewed PDGFRB allele fractions, in sporadic fusiform aneurysms, ranged from 5·6 to 
21·4% (Fig. 2A) also consistent with post-zygotic, somatic variants. These results were also 
confirmed by next generation sequencing after independent primer pair amplification across the 
variant locations, with similar allele fractions (Fig. S5 and S7 in the Supplementary Appendix). 
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Two of the PDGFRB missense variants observed (p.(Tyr562Cys) and p.(Asp850Val)) have 
recently been found in sporadic myofibromas22,23. None of the variants we detected in intracranial 
aneurysms were seen in >120,000 normal genomes (dbSNP, 1000Genomes, NHLBI-EVS, 
gnomAD) which support their pathogenicity and suggest that they may be embryonic lethal. These 
variants altered conserved regions and were predicted to be protein altering and pathogenic by 
PolyPhen2, SIFT and MutationTaster (Fig. S9 in the Supplementary Appendix).  
In fusiform aneurysms, missense variants and in-frame deletions occurred in either the -
ArgTyrGluIleArg- motif of the juxtamembrane region or adjacent -AspPheGly- motif in the 
activation loop (Fig. 3A-C, Fig. S9 in the Supplementary Appendix) of PDGFRB. Disruption of 
juxtamembrane region auto-inhibitory sites causes constitutive activation24,27. All four variants 
occur in known homologous PDGFRA and KIT “hot spots” within the juxtamembrane or activation 
loop of the kinase domains24,25. The conserved residues are found in all tyrosine protein kinases, 
and the analogous residues (Tyr555 and Tyr552) in the PDGFRA and KIT kinases are somatically 
altered in cancers24,25 (Fig. 3B). The aneurysm alterations in PDGFRB are predicted to result in 
p.Tyr562Cys and p.Tyr562_Arg565del. Aligned amino-acid sequences of the activation loops of 
human KIT, PDGFRA and PDGFRB start and end with residues - AspPheGly - and -AlaProGlu-. 
The two alterations within the kinase loop known to be important for autoregulation24,25,28,29 were 
p.(Asp850Tyr) and an in-frame deletion/insertion spanning this region (Fig. 3C). These data 
suggest that variants found in cerebral aneurysms act via gain-of-function mechanisms. Deep 
targeted sequencing of the genes coding for the kinases KRAS, PDGFRA, BRAF, TGFBR1 and 
TGFBR2 identified no variants in the cohort of 50 aneurysms, consistent with an etiology specific 
to PDGFRB. 
Several heterozygous germline or mosaic gain-of-function variants in PDGFRB result in 
8 
 
infantile myofibromatosis (IM, MIM #228550) or sporadic myofibromas, while single 
heterozygous germline variants were found in the rare Kosaki overgrowth (MIM #616592) and 
Penttinen syndromes (MIM #601812) (Fig. 3 and Fig. S10 in the Supplementary Appendix). 
Several other heterozygous germline loss-of-function variants cause primary familial brain 
calcification (PFBC, MIM #615007). None of the above phenotypes were found in our four 
aneurysm individuals (Fig. S10 in the Supplementary Appendix). Individuals with genome copy 
number alterations, including chromosome 5 deletions encompassing PDGFRB, have been 
associated with developmental delay but not with aneurysm development26. Mice deficient in 
Pdgfb or Pdgfrb die from multiple developmental defects including hemorrhages due to a lack of 
pericytes and vascular smooth muscle cells in blood vessels17-20. Pdgfrb activating mutations in 
mice cause vascular smooth muscle cell de-differentiation, hyperplasia and increased extracellular 
matrix synthesis20. The wide range of phenotypes suggests a complexity of PDGFRB function and 
downstream signaling that is likely due to cell lineage and developmental timing specific 
expression. 
To study the functional status of PDGFRB variants, we performed assays using cells 
collected from skin punches of the index individual (healthy and affected regions) and site-directed 
mutagenesis was performed using the QuickChange II Site-Directed Mutagenesis Kit (Catalog 
#200518, Agilent Technologies). For details, see the Supplementary Appendix. Ligand binding 
induces PDGFRB dimerization and activating autophosphorylation in trans. Phosphorylation on 
multiple tyrosine residues creates docking sites for signaling proteins, including 
phosphatidylinositol-3 kinase (PI3K), AKT, STAT transcription factors, and phospholipase C 
(PLC)27-31. Starved mosaic fibroblasts harvested from the index individual, predicted to express 
the Tyr562Cys variant, had higher basal levels of pPDGFRB, pSRC (Tyr416), pAKT (Ser473) 
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and pERK 1/2 (Thr202/Tyr204) (Fig. 4A, B). PDGFBB was able to further autophosphorylate 
PDGFRB and activate downstream signaling (Fig. 4B). To investigate the pathogenic mechanism 
of all discovered variants, we ectopically expressed wild-type (WT), aneurysm-associated variants, 
and two controls in HEK cells (Fig. 4C). All four aneurysm-associated variants caused higher 
levels of autophosphorylation of PDGFRB when compared to WT. We next tested the ability of 
the multi-targeted receptor tyrosine kinase inhibitor sunitinib (Sutent) to down regulate auto-
phosphorylation of PDGFRB variants (Fig. 4D). While all intracranial aneurysm variants exhibited 
relative resistance to sunitinib compared to WT PDGFRB under these conditions, three could be 
strongly inhibited. In contrast, the p.(Asp850Tyr) variant exhibited marked resistance to sunitinib 
under these conditions. Interestingly, kinase inhibitor resistance was also reported for 
p.(Asp850Val), similar to the p.(Asp842Tyr) PDGFRA and p.(Asp816Val) KIT variants in 
gastrointestinal stromal tumors24,25. 
Exome sequencing of the index individual allowed study of the role of somatic alterations 
in aneurysm formation. A single post-zygotic, somatic variant in PDGFRB, predicted to cause a 
gain-of-function protein, was discovered. This observation in the index individual provided the 
proof in principle that alterations in PDGFRB might be found in sporadic, non-mosaic, individuals. 
Here we describe variants of PDGFRB as a cause of single and multiple fusiform aneurysms. The 
role of somatic mosaicism has been described in overgrowth syndromes (AKT18, PIK3CA9), 
Sturge-Weber Syndrome (GNAQ11), head and neck12-15 and cerebral arterial-venous malformations 
(KRAS16). Following this theme, PDGFRB activating variants of the cerebral vasculature seem to 
drive aneurysm formation. We describe the first reported genetic cause of any type of sporadic 
intracranial aneurysm: activating variants in PDGFRB. We used exome sequencing and targeted 
deep sequencing to explore the genetic landscape of cerebral aneurysms. A somatic point variant, 
10 
 
predicted to result in a tyrosine to cysteine (p.(Tyr562Cys)) change, within the conserved, auto-
inhibitory, juxtamembrane region of PDGFRB was identified. To explore the possibility of 
additional driving mutations and genetic similarities we performed exome sequencing in all 
fusiform aneurysms. This confirmed the following: 1. Exome sequencing of PDGFRB-variant 
fusiform aneurysms revealed no additional detectable recurrent gene alterations consistent with a 
causal relationship, 2. Two of the fusiform aneurysms carried wild type PDGFRB and had no 
evidence of novel driver variant and 3. Exome sequencing of multiple abnormal tissue specimens, 
from PDGFRB-variant patients, revealed a definitive role for somatic mosaicism in two of four 
individuals. 
Activating PDGFRB variants underlie sporadic fusiform aneurysms, suggesting an 
important role in cerebral artery angiogenesis. Four of six fusiform aneurysms carried PDGFRB 
activating variants, highlighting the importance of this pathway. Two fusiform aneurysms did not 
harbor PDGFRB alterations even on deep sequencing, suggesting another gene or mechanism in 
formation or that ultra-low variant allele fractions were not detected. While our exome sequencing 
was sensitive enough (150x coverage) to detect PDGFRB variants, it is possible that we were 
unable to detect ultra, low-level variants in other novel contributing genes. Re-sequencing of 
PDGFRB, with on average 400x coverage, in both wild-type fusiform and saccular aneurysms 
should detect allele frequencies down to 1%. Although we examined pathologic tissue specimens, 
we concede our techniques would not allow detection of low frequency fractional (<1%) variants 
with certainty.  
Protein kinase activation by somatic variant or chromosomal alteration is a common 
mechanism of overgrowth syndromes8,9, vascular malformations10-16 as well as tumorigenesis24,25. 
While variants in PDGFRA and PDGFB may be oncogenic, very few variants of PDGFRB have 
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been described in cancer24 (Fig. 3D). Chromosome translocations causing gene fusions have been 
reported in rare cases of myeloid neoplasms with eosinophilia that were sensitive to imatinib34. 
Collectively, our functional studies demonstrate elevated auto-phosphorylation of variant 
PDGFRB and consequent activation of AKT, SRC and ERK. PDGFRB is essential in the 
propagation of cerebral pericytes and is a surface marker for these cells, which are thought to give 
rise to the vascular smooth muscle layer of the arterial media18-21,27-31. Since PDGFRB is highly 
expressed in and plays an essential role in pericyte development18-21,27-31, our data suggest that 
aneurysms may originate from cerebral pericytes, vascular smooth muscle cells or their 
progenitors.  
Alterations result in activated alleles of PDGFRB with differential sensitivity to kinase 
inhibitors, suggesting a potential role for therapeutic intervention. Direct inhibition of activated 
receptor tyrosine kinases may be a promising approach to aneurysm therapy, and further research 
is warranted. Where resistance is encountered, for example in the p.(Asp850Tyr) variant described 
in this study, kinase inhibitors to downstream targets (e.g. AKT, ERK) represent an alternative 
strategy. The PDGFRB variants detected in both fusiform intracranial aneurysms and 
myofibromas cluster in the same two regions (juxtamembrane and activation loop of the kinase 
domain), with one variant in common (p.(Tyr562Cys)) and another involving the same codon 
(p.(Asp850Tyr) in intracranial aneurysms, p.(Asp842Val) in myofibromas). It is striking that none 
of the variants are reported to occur in the germline, but are tolerated in a mosaic pattern. It is 
unknown if PDGFRB variants cause both cerebral aneurysms and myofibromas in the same 
individual but there may be overlap. While the individuals described in this manuscript had no 
evidence of myofibromas, renal and iliac aneurysms have been reported in an individual with IM35. 
More research is necessary to understand the role of age or timing specific intracranial aneurysm 
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formation. PDGFRB targeted therapy for treatment of severe IM in an individual with a 
heterozygous germline mutation PDGFRB has been reported36.  
Fusiform aneurysms of the neurovascular tree are difficult to treat and can rupture, cause 
vessel occlusion or mass effect on nearby perforator vessels resulting in neurologic deficits1,2,32,33. 
Securing of the aneurysm, prior to rupture with maintenance of cerebral blood flow are the goals. 
Fusiform cerebral aneurysms are difficult to treat with surgery or with endovascular techniques, 
such as stent or coil reconstruction32,33. Regardless of treatment option, outcomes for fusiform 
aneurysm are poor32,33, highlighting a need for improved therapies for this select group of vascular 
lesions. The data presented suggests that some fusiform cerebral aneurysms are caused by 
activating variants in PDGFRB. The identification of PDGFRB variants in a subset of human 
fusiform aneurysms and the association between variant and kinase inhibitor efficacy extend the 
role of overactive kinase activity in vascular pathogenesis. The striking differences in PDGFRB 
variants found in fusiform versus saccular aneurysms raise the possibility of unique genetic 
landscapes and molecular pathogenesis underlying this heterogeneity. Our cohort is limited, and 
adequate study will require a much larger cohort from multiple centers. These findings provide a 
model for understanding post-zygotic genetic alterations causing sporadic aneurysms, which may 
occur over the lifetime of individuals. The role of somatic PDGFRB variants in fusiform 
aneurysms has shed light on a pathogenic mechanism in intracranial aneurysms. This finding may 
aid in the identification of additional causative somatic intracranial aneurysm genes. Identification 
of recurrent PDGFRB alterations provide an avenue of study for tyrosine kinase inhibition as a 
future therapeutic strategy in fusiform cerebral aneurysms. 
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Figure 1: Index individual phenotype and PDGFRB genotype. A, Body map skin mosaicism 
(in red) and specimens used for exome sequencing. B, Cutaneous appearance. C, Angiogram 3D 
reconstruction of right vertebral injection illustrating a giant vertebral fusiform aneurysm. D-I, 
Abnormal extra cranial soft tissue vasculature associated with the occipital artery (Specimen 
MOS-WES-3): D, Low power (4x) and E, medium power (10x) magnification of a hematoxylin 
and eosin (H&E) stained slide demonstrating a markedly affected vessel with focal evidence of 
dissection (arrowhead).  There is severe intimal hyperplasia and the tunica media (*) becomes 
markedly attenuated. F, Low power (4x) and G, medium power (10x) magnification of Gomori 
trichrome (GT) stained slide with the intima (**) and the tunica media (*) highlighted.  H, Low 
power (4x) and I, medium power (10x) magnification of Verhoeff-Van Gieson (VVG) stained 
slide.  The internal elastic lamina (*) associated with the relatively better preserved fragment of 
tunica media, as well several areas with attenuated internal elastic lamina are highlighted (**). J, 
Specimen MOS-WES-6, medium power magnification (10x), H&E stained slide of an 
unremarkable left arm radial artery.  Well-defined intimal layer, tunica media, and tunica 
adventitia along with an intact internal elastic lamina (*) are visualized.  K, Specimens used for 
exome sequencing and coverage of the p.Tyr562Cys variant. L, Next generation sequencing reads 
across the area of the missense variant, with the variant nucleotides (C) in blue. The reference 
nucleotide and amino acid sequences are at the bottom.  
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Figure 2: Sporadic fusiform aneurysms harbour PDGFRB variants. A, Demographics of 
sporadic fusiform aneurysm subjects and variants, including age at treatment. B, C, F, Angiogram 
and/or 3D reconstruction from angiogram representative images illustrating the fusiform 
morphology. D and E, Representative H&E stained sections of specimen VAL-44 at low (1·25x) 
and medium (10x) magnification showing a markedly affected vessel with vascular wall 
attenuation, an intraluminal thrombus with early organization and dissecting haemorrhage. The 
tunica media (*) is focally present and becomes attenuated (**). G, H&E stained sections at 
low magnification (1·25x) of specimen VAL-61 stained showing a representative portion of the 3 
cm aneurysm with a large partially organizing thrombus and a markedly attenuated vascular wall. 
Abbreviations: AF = Allele frequency, ICA = Internal carotid artery, MCA = Middle cerebral 
artery, PCA = Posterior cerebral artery, RCCA = Right common carotid artery. 
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Figure 3: Variants in PDGFRB within the juxtamembrane region and the kinase activation 
loop found in fusiform aneurysms. A, Schematic representation of the PDGFRB protein, amino 
acid sequence of the two hotspots, and the location of variants. Germline and somatic PDGFRB 
variants with known or implied functional consequences in other syndromes and diseases included 
for comparison. B, Homologous juxtamembrane amino acid sequences for KIT, PDGFRA and 
PDGFRB and location of aneurysm variants. C, Homologous kinase domain activation loop amino 
acid sequences for KIT, PDGFRA and PDGFRB and location of aneurysm mutations. D, All 
somatic variants reported in the COSMIC database with possible activating consequences 
(missense and in-frame insertion/deletions) in KIT, PDGFRA and PDGFRB. Notice the increased 
frequency of variants in both juxtamembrane region and kinase activation loop of KIT and 
PDGFRA. There is a comparative lack of variants reported in PDGFRB.  
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Figure 4: PDGFRB variants are constitutively phosphorylated, sensitive to sunitinib kinase 
inhibition and activate downstream signalling pathways. A, Western blot analysis of non-
starved normal (wild-type PDGFRB) and mosaic affected Tyr562Cys fibroblast cells from the 
index individual. B, Western blot analysis of starved and PDGF-BB stimulated normal (wild-type 
PDGFRB) and mosaic affected Tyr562Cys fibroblast cells from the index individual. C, Western 
blot analysis of HEK cells stably expressing the described aneurysm variants and Trp566Arg (IM 
- gain of function) and Asp844Gly (PFBC - loss of function) control variants showing varying 
levels of phosphorylation and expression of PDGFRB. D, Sensitivity of PDGFRB auto-
phosphorylation to sunitinib. 
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